CUMBERLAND PHARMACEUTICALS INC

Listed Company

CPIXCIK 0001087294NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsTennesseeFY ends Dec 31

Period

FY 2025

Revenue

$44.52M

Net Income

$-2.84M

Total Assets

$76.82M

Equity

$24.88M

Shares Out

14.98M

Op. Cash Flow

$4.93M

CPIX$6.76+79.31% · past yearDBEQ Basic

Daily closing prices

Business

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription pharmaceuticals for hospital acute care, gastroenterology and oncology markets. The company markets seven FDA-approved products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ and Talicia, with one clinical-stage product candidate, ifetroban, in Phase II development for rare diseases. Cumberland sells through dedicated hospital, field and oncology sales divisions in the United States and partners with international distributors to commercialize products in other countries.

Summary from 10-K filed 2026-03-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenues	45	38	40	42	—
Cost of products sold	7	7	6	9	9
Selling and marketing	19	17	18	17	15
Research and development	6	5	6	7	6
General and administrative	12	11	11	10	10
Amortization and impairment	4	5	8	5	4
Total costs and expenses	47	44	49	48	44
Operating loss	−3	−6	−10	−6	−8
Interest income	476,748	334,444	286,854	98,405	26,081
Other income - gain on insurance proceeds	0	237,089	346,800	611,330	0
Interest expense	−495,990	−605,508	−667,861	−585,995	−98,031
Loss before income taxes	−3	−6	—	—	—
Income tax (expense) benefit	−40,000	20,000	−45,769	−68,850	−34,891
Equity in loss of investee	−13,220	0	—	—	—
Net loss	−3	−6	−6	−6	−4
Net (income) loss at subsidiary attributable to noncontrolling interests	28,583	−36,055	51,446	79,798	95,212
Net loss attributable to common shareholders	−3	−6	−6	−6	−4
Basic (in USD per share)	−0.19	−0.46	−0.44	−0.38	−0.24
Diluted (in USD per share)	−0.19	−0.46	−0.44	−0.38	−0.24
Basic (in shares)	15	14	14	15	15
Diluted (in shares)	15	14	14	15	15

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	11	18	18	20	27
Accounts receivable, net	17	12	10	13	7
Inventories, net	6	4	5	10	8
Prepaid and other current assets	2	3	3	3	3
Total current assets	37	36	36	46	46
Non-current inventories	9	11	13	8	9
Property and equipment, net	264,724	277,365	367,903	284,039	442,635
Intangible assets, net	14	18	23	31	24
Goodwill	914,000	914,000	914,000	914,000	882,000
Operating lease right-of-use assets	8	6	7	5	1
Investments	4	0	—	—	—
Other assets	3	3	3	3	3
Total assets	77	76	82	93	84
Accounts payable	19	14	14	11	10
Operating lease current liabilities	467,774	356,508	348,092	172,910	969,677
Revolving line of credit - current	0	5	0	—	—
Other investment liabilities	5	0	—	—	—
Other current liabilities	13	12	14	18	—
Total current liabilities	37	32	28	29	19
Revolving line of credit - long term	5	10	13	16	15
Operating lease non-current liabilities	4	5	5	5	90,016
Total other long-term liabilities	6	6	6	8	7
Total liabilities	52	53	53	57	42
Common stock no par value; 100,000,000 shares authorized; 14,956,627 and 13,952,624 shares issued and outstanding as of December 31, 2025 and 2024, respectively	52	47	47	47	48
Accumulated deficit	−27	−24	−17	−11	−6
Total shareholders equity	25	23	30	36	43
Noncontrolling interests	−336,100	−307,517	−343,572	−292,126	−212,328
Total equity	25	23	29	36	43
Total liabilities and equity	77	76	82	93	84

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	4	5	5	5	5
Amortization of operating lease right-of-use asset	1	1	834,500	0	—
Loss on co-commercialization investment	13,220	0	—	—	—
Disposal of assets	0	2,691	20,256	0	—
Stock-based compensation	408,320	301,895	365,040	447,503	741,867
Increase (decrease) in non-cash contingent consideration	46,569	−1	−1	−2	—
Increase in cash surrender value of life insurance policies over premiums paid	−142,927	−139,953	−124,736	613,657	−282,207
Noncash interest expense	23,185	28,313	15,523	11,237	34,053
Life insurance proceeds	0	−237,089	−346,800	−611,330	0
Accounts receivable	−5	−2	3	−6	6
Inventories, net	2	2	−23,143	911,078	5
Other current assets and other assets	−231,829	189,112	65,684	689,260	−35,568
Operating lease liabilities	−836,100	2	4	0	—
Accounts payable and other current liabilities	7	−991,359	−1	15	−757,591
Other long-term liabilities	−477,642	−153,771	−1	419,659	−1
Net cash provided by (used in) operating activities	5	−612,186	6	8	6
Additions to property and equipment	−97,903	−66,461	−281,268	−102,148	−103,532
Additions to intangible assets	−84,402	−113,253	−171,783	−2	−250,930
Net investment in manufacturing	−2	0	0	−14	0
Other investment	−2	0	—	—	—
Increase in cash surrender value of life insurance policies	−47,000	0	—	—	—
Life insurance policy proceeds received	0	237,556	347,356	877,597	0
Net cash provided by (used in) investing activities	−5	57,842	−105,695	−14	−501,893
Borrowings on line of credit	0	38	31	53	59
Payments on line of credit	−10	−36	−35	−52	−59
Proceeds from ATM offering, net	5	0	—	—	—
Payments made in connection with repurchase of common shares	−263,478	−579,049	−740,533	−1	−1
Cash settlement of contingent consideration	−2	−2	−3	−2	−2
Net cash provided by (used in) financing activities	−7	196,904	−7	−2	−4
Net decrease in cash and cash equivalents	−7	−357,440	−1	−7	2
Interest	441,677	569,230	647,137	523,161	63,978
State income taxes	−3,525	15,000	108,823	3,300	−327
Total cash paid included in measurement of lease liability	836,100	863,320	804,818	1	—
Change in unpaid invoices for intangible asset additions	4,727	530	−51,895	−2	−43,471
Change in unpaid invoices for offering costs	62	−69,701	69,001	−94,689	—
Lease liability obtained from right-of-use assets	438,311	128,039	1	5	0
Other investment liability	2	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CUMBERLAND PHARMACEUTICALS INC's CIK number?

CUMBERLAND PHARMACEUTICALS INC's SEC CIK number is 0001087294 (1087294). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CUMBERLAND PHARMACEUTICALS INC's SEC filings?

All of CUMBERLAND PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CUMBERLAND PHARMACEUTICALS INC last report earnings?

CUMBERLAND PHARMACEUTICALS INC (CPIX) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001087294-26-000046). This is CUMBERLAND PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is CUMBERLAND PHARMACEUTICALS INC's most recent earnings 8-K?

CUMBERLAND PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001087294-26-000046. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CUMBERLAND PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →